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     A balance between excitatory and inhibitory neurotransmissions in brain is an essential factor for 
the proper function of the brain. The amino acid gamma-aminobutyric-acid (GABA) is considered as 
the major inhibitory neurotransmitter in brain. Thus, GABAergic neurons play a key role in regulating 
behavior. Previous data have revealed the complex subunit structural design for GABAA receptor 
channel, in which a pentameric assembly resulting from 5 of at least 21 subunits, grouped in the eight 
classes alpha (α1-6), beta (β1-4), gamma (γ1-4), delta, pi (π), epsilon (ε), theta (θ) and rho (ρ1-3) 
permits an immense number of putative receptor isoforms. GABAARs are highly diversed in the 
central nervous system in which this diversity may be related to some mental disorders. Any alteration 
in expression of the GABAA receptor genes causes neurophysiological and functional consequences 
that might be associated with neurological disorders. Some neuropsychiatric disorders, such as 
anxiety, epilepsy and sleep disorders, are effectively treated with therapeutic agents that act on the 
GABAA receptor. In this article, the contribution of GABAA receptor deficits to central nervous 
system disorders, in particular anxiety disorders, epilepsy, schizophrenia and insomnia, will be 
reviewed. The better understanding of GABA and its receptors may help us to find novel therapeutic 
agents for treatment of mental disorder in future research. 
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INTRODUCTION 
     The amino acid gamma-aminobutyric-acid 
(GABA) is the major inhibitory 
neurotransmitter in the CNS [1, 2] that 
mediates most of its effects through receptors 
termed GABAA. Previous data have revealed 
the complex subunits structural design of this 
receptor channel, in which a pentameric 
assembly resulting from five of at least 21 
subunits, grouped in the eight classes alpha 
(α1-6), beta (β1-4), gamma (γ1-4), delta, pi, 
epsilon, theta, and rho (ρ1-3) [3-5] permits an 
immense number of putative receptor 
isoforms. These varieties are extended the 
existence of several splicing variant forms, for 
instance of the α6, β2 and γ2 subunits [6]. The 
subunit combination of GABAA receptor 
determines the specific effects of allosteric 
modulators as benzodiazepines (BZs), 
barbiturates, steroids, and general anaesthetics, 
some convulsants, polyvalent cations, and 
ethanol. These agents act through different 
binding sites some of which are not identified 
yet [7, 8]. Drugs and endogenous ligands bind 
either to the extracellular domain or channel 
domain of the GABAA receptors and act as 
positive or negative allosteric modulators [9]. 
In heterologous expression systems, the 
presence of alpha, beta subunits are needed for 
functional channels while, gamma subunits are 
required to mimic the full repertoire of native 
receptor for responses to drugs. The 
knowledge of the complex pharmacology of 
GABAA receptors might eventually enable 
site-directed drug design to elaborate our 
understanding of GABA-related disorders and 
of the complex interaction of excitatory and 
inhibitory mechanisms in neuronal processing. 
To understand the role of GABAA receptors in 
mental disorder many methods including 
molecular and electrophysiological techniques 
have been used. In the present study we have 
shown the role of GABAARs in some mental 
disorders.  
 
Structure and molecular biology of GABA 
receptors 
     The ligand-gated ion channels (LGICs) 
super family share a common proposed 
structure. They have a long extracellular 
amino terminus (around 200 amino acid), 
thought to be responsible for ligand channel 
interactions and forms agonist binding site, 
and four transmembrane (TM) domains and a 
large intracellular domain between TM3 and 
TM4 [2, 10]. The TM3-TM4 loop is an 
important site for regulation by 
phosphorylation and for localization at 
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synapses [11]. It is thought that TM2 forms the 
lining segment of the ion channel. The 
extracellular amino terminus is believed to 
incorporate neurotransmitter and some 
modulator binding sites and it contains a 
conserved motif, the so-called Cys loop 
(cysteine loop). The Cys-loop is characterized 
by two cysteine residues spaced by thirteen 
otherwise largely divergent amino acid 
residues (Figure.1). This structure is common 
within acetylcholine (ACh), glycine and type 3 
serotonin (5-HT3) receptor as well.  
 
 
Figure 1. Ligand gated ion channels are composed of five 
peptide units. Each unit has an N-terminal domain, four 
transmembrane domains, a large extracellular loop 
between M3 and M4 and a C-terminus [116]. 
 
Channels in GABAA and glycine receptors are 
anion-selective, whereas in the ACh and 5-
HT3 receptors are cation-selective [12]. There 
is a significant sequence homology in each 
receptor gene family. In GABAA receptor 
subunits the region between TM3 and TM4 
shows a little or no sequence homology, 
suggesting that this domain can tolerate many 
changes without affecting any possible 
functional role [13, 14]. GABAA receptors are 
large proteins (450-627 amino acids in length) 
embedded in the cell membrane of neurons. 
The channel is formed in the centre of receptor 
that consists of five protein molecules, or 
subunits [15]. GABAA receptors are activated 
directly by GABA. In this phenomenon they 
mediate fast response to GABA and open 
channel to allow the inward passage of 
chloride and bicarbonate ions from outside the 
cell to inside it. 
 
Chromosomal localization of GABAA 
receptor genes 
     It has been found that each GABAA 
receptor subunit is encoded by homologous, 
distinct genes. Many of the subunit genes are 
organized in  and  gene 
clusters on different chromosomes [16, 17]. In 
humans, the  subunit genes are 
localized on chromosome 4p14-q12. The 1 
and 4 genes, which are separated by less than 
60-kb, are arranged in the head to head 
orientation [17]. The 1 transcription unit faces 
the tail of 2. The , and 1 subunit 
mRNA are predominately expressed in the 
undifferentiated neuroepithelium of rat embryo 
[18]. During postnatal development, down 
regulation of the , and 1 subunits 
occurs in some specific region whereas 
expression levels of most other subunits 
increase. Highly expression of the , and 
1 genes in the hippocampal formation of the 
adult rat [19], shows that cluster organization 
may be necessary to preserve region-specific 
gene transcription.  
     The most abundant GABAA receptor 
subunit genes encoding are found in a 2-
 cluster on chromosome 5q31.2-q35 
[17, 20-24]. The 2 and 6 genes are 
separated by less than 60-kb, with 
transcription units facing in opposite directions 
[17]. The colocalization of the , and 2 
subunits may be related to their coordinate 
gene regulation throughout the nervous 
system; however, direct observation of 
coordinate regulation has not been reported. 
The 6 gene that is head-to-head with 2 is 
expressed only in cerebellar granule cells [25], 
suggests that there is also independent 
regulation of transcription for individual 
members in this gene cluster. 
    The  GABAA receptor subunit 
genes are localized on chromosome 15q11–
q13 [17, 26-31]. Lastly, the putative  
gene cluster on chromosome Xq28 is 
analogous to the cluster on chromosome 15 
[16, 17, 32, 33]. The -subunit gene is 
analogous to , and  has the same position 
and transcriptional orientation as the -subunit 
gene in other clusters.  
     Gene expression can be controlled at 
multiple levels of transcription, alternative 
splicing, mRNA stability, translation, post-
translational modification, intracellular 
trafficking, and protein degradation. However, 
gene regulation is predominantly controlled at 
the level of transcription initiation [34, 35]. 
Any abnormal alteration during gene 
expression could result in changes in function 
and could lead to mental disorders.  
 
Distribution of GABAA receptor subunits in 
the CNS 
     A variety of studies using in situ 
hybridization [25, 36] and 
immunohistochemistry [37-41]  have indicated 
the distribution of GABAA receptor subunits in 
the brain. The GABAA receptor α1, β1, β2, β3,  
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and γ2 are found throughout the brain with 
different distribution levels. The α2, α3, α4, 
α5, α6, γ1, and δ subunits are found in certain 
regions of the brain (Table 1). Mehta et al 
(1999) reported the percentage of the binding 
sites immunoprecipitated by antisera to 
various subunits of GABAA receptors in the 
adult brain regions. These percentages are as 
follows: α1 = 70-90%, α2 = 4-28%, α3 = 12-
24%, α4 = 0-15%, α5 = 4-14%, α6 = 30-39% 
(cerebellum), β1 = 2-32%, β2 = 55-96%, β3 = 
19-52%, γ1 = 0-19%, γ2 = 50-94%, γ2S = 31-
52%, γ2L = 37-65%, γ3 = 0-18%, and δ = 0- 
 
23% [43]. These results are in a good 
agreement with in situ hybridization data 
which showed in the brain that γ1 and γ3 
mRNA are expressed in much smaller amounts 
relative to γ2 mRNA [25, 36, 44]. Although 
these data do not show the regional 
distribution of GABAA receptor subunits, they 
show which subunits are abundant in the brain. 
Distribution of GABAA receptor subunits in 
the brain are summarised in table 1. Gaba 
receptor also could be seen in other tissue far 
from CNS such as sperm [45]. 
 
Table 1. Regional distributions of GABAA receptor subutints in the brain (Sieghart, 2002) 
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Pharmacology of GABAA receptors 
      More than one hundred agents act on 
GABAA receptors. These agents act in 
different binding sites which some are not 
known yet [46]. Drugs and endogenous 
ligands act as positive or negative 
allosteric modulators on GABAA 
receptors. Compounds bind on either 
extracellular domain or channel domain of 
the receptor and act as positive or negative 
modulators [2]. Benzodiazepines are 
positive modulators acting on the 
extracellular domain, whereas -carbolines 
act mainly as negative modulators. The 
presence or absence of the 2 subunit in 
the structure of the GABAA receptor can 
influence the action of positive allosteric 
modulators [47]. The effect of compounds 
bind on channel the domain can be 
positive or negative. Barbiturates and 
steroid hormones act as positive allosteric 
modulators, whereas pregnenolone and 
picrotoxin act as negative modulators. 
However their effects do not depends on 
the structure of the receptors [47-49]. 
Benzodiazepines have been widely 
prescribed since chlordiazepoxide was first 
introduced in 1960; and because of their 
safety and efficacy benzodiazepines 
became the most prescribed drugs in the 
1960s and 1970s. However, because of 
benzodiazepines side effects and drug 
abuse the use of benzodiazepines have 
fallen in recent years, but they are still 
highly prescribed drugs [50]. 
Benzodiazepines the one of these agents 
use to treat anxiety have side effects such 
as sedation, ataxia, amnesia, tolerance, and 
physical dependence. Because the 
physiological and pharmacological role of 
various native GABAA receptor assemblies 
is not yet known, it is not easy to 
synthesize compounds selective for 
particular receptor assembly to get a 
desired therapeutic effect without any 
serious side effect. All GABA receptors 
are sensitive to GABA. The binding of 
GABA to specific sites on the receptor 
results in the opening of an intrinsic ion 
channel and the flux of chloride into the 
cell, which leads to a hyperpolarization of 
the cell membrane and an increase in the 
inhibitory tone. The GABAA receptors are 
targets for many important drugs such as 
benzodiazepines, general anaesthetics, 
steroids, convulsants and barbiturates [51]. 
Benzodiazepines mediate their sedative, 
amnesic and anxiolytic actions via binding 
to GABAA receptors. The sensitivity of 
GABA receptors to benzodiazepines 
depends on the GABA receptor subunits 
composition and is different from one 
region of the brain to another [52]. It is 
suggested that  subunit has a role as 
important as subunit in determining 
benzodiazepines sensitivity [53].  Different 
variants of the  subunit can influence both 
affinity and efficacy of various 
benzodiazepines site ligands and also the 
type of  subunit can influence the affinity 
and efficacy of a number of 
benzodiazepines such as zolpidem. 
Receptor combinations which include the 
1 receptor subunits display, 
benzodiazepines type one pharmacology 
and bind diazepam, zolpidem and other 
benzodiazepines with high affinity, while 
those receptors including the 2, 3, and 
5 subunits display benzodiazepines type 
two pharmacology and confer low affinity 
for this ligand, whereas the 4 and 6 
subunits confer benzodiazepines 
insensitivity [54]. The crucial amino acids 
responsible for potent action of 
benzodiazepines are located within the N-
terminal domains of  and , within the 
putative second and third transmembrane 
domains [55]. In one study various 
compounds of benzodiazepines were 
examined on three different human 
GABAA receptor combinations (21, 
212S, 211). The data showed 
significant differences among these 
GABAA combinations. The 1 subunit in 
comparison to 2 subunit can confer a 
different pharmacological profile with 
regard to benzodiazepine site ligands [53]. 
The patch-clamp technique will be used to 
facilitate the further characterisation of 
these drugs and their GABAA receptors. In 
this thesis the effects of some of the drugs 
on GABAA channels was examined. 
Understanding the basic mechanism of 
operation of the GABAA receptors may 
possibly result in more specific drugs and 
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better treatments of some of the mental 
disorders. One way make pharmacological 
screening of GABA subunits easy is using 
an anion-sensitive yellow fluorescent 
protein-based assay [56]   
     The action of nM and M concentration 
of diazepam on 2 recombinant 
expressed into Xenopus oocytes is 
different at low concentration of GABA 
[55]. At M concentration diazepam action 
is independent of the 2 subunit. Using 
mutation of rho subunit of corresponding 
TM2 and TM3 residues and application of 
diazepam support this results. Together 
these data suggest that diazepam, at low 
concentration of GABA creates two 
distinct components of potentiation. 
Gamma subunits are relatively insensitive 
to Zn
2+
 compared to subunit receptors 
[57]. 
 
GABAA receptors and mental disorder 
     Studies on GABAA receptors show that 
these receptors are involved in the pathology 
of several neurological and psychiatric 
diseases, such as epilepsy, anxiety, alcoholism 
[58], Angelman’s syndrome [59], autism [60], 
depression [61], premenstrual syndrome [62-
64], sleep disorders [65], and Alzheimer’s 
disease [64]. Some psychiatric disease such as, 
spasticity, and stiff-person syndrome, are 
related to lack of GABAergic function in the 
brain.  
     GABA transmission plays a key role in 
controlling seizure activity. The exact nature 
of its effect depends on the particular position 
in the brain and the pathway involved. Animal 
studies have helped to describe specific brain 
regions such as the substantia nigra that are 
vital in controlling seizure activity. 
Antiepileptic drugs such as vigabatrin, a drug 
developed to treat resistant epilepsy, can 
increase GABA transmission in these regions 
and may thereby afford seizure protection 
[66].  
     The role of gamma-aminobutyric acid 
(GABA) in depression and anxiety has been 
described. New data from both animal and 
human experimentation have helped define the 
key role for this transmitter in both these 
mental pathologies [67]. Dysfunction of the 
gamma-aminobutyric (GABA) in central 
nervous system has long been associated with 
anxiety disorders [68-70]. In both human and 
animal studies, positive modulators of GABA 
receptors generally possess anxiolytic activity, 
whereas negative modulators create 
anxiogenic-like effects [68]. Various GABA 
analogs and agents affecting transmitter 
metabolism to enhance GABAergic tone have 
also been reported to exert anxiolytic effects 
[71, 72]. Chronic alcoholism leads to localized 
brain damage, which is eminent in superior 
frontal cortex but mild in motor cortex. The 
probability of developing alcohol dependence 
is associated with genetic markers. GABAA 
receptor expression differs between alcoholics 
and controls [73, 74].  
Many researchers guess that GABAergic 
dysfunction plays an important role in the 
mechanism of neural impairment in Angelman 
syndrome [75, 76]. 
     First round reports have showed altered 
expression of GABA receptors in the brains of 
subjects with autism suggesting 
GABA/glutamate system dysregulation. 
Significant decreases in GABRA1, GABRA2, 
GABRA3, and GABRB3 in parietal cortex 
have been reported. These results reveal that 
GABAA receptors are reduced in the brain 
regions that have previously been associated in 
the pathogenesis of autism, suggesting 
widespread GABAergic dysfunction in the 
brains of subjects with autism [77, 78]. 
     Adult neurogenesis adjusts plasticity and 
function in the hippocampus, which is critical 
for memory and vulnerable to Alzheimer's 
disease (AD). Promoting neurogenesis may 
improve hippocampal function in AD brains. 
However, how amyloid β (Aβ), the key AD 
pathogen, affects the development and 
function of adult-born neurons remains 
unknown. Adult-born granule cells  (GCs) in 
human amyloid precursor protein (hAPP) 
transgenic mice, an AD model, showed greater 
dendritic length, spine density, and functional 
responses than did controls early in 
development, but were impaired 
morphologically and functionally during later 
maturation. Early inhibition of GABAA 
receptors to suppress GABAergic signaling or 
late inhibition of calcineurin  to enhance 
glutamatergic signaling normalized the 
development of adult-born GCs in hAPP mice 
with high Aβ levels. Aβ-induced increases in 
GABAergic neurotransmission or an 
imbalance between GABAergic and 
glutamatergic neurotransmission may 
contribute to impaired neurogenesis in AD 
[79].  
     In comparison to glutamatergic and 
cholinergic systems, the GABAergic system is 
relatively spared in AD, but the precise 
mechanisms underlying differential 
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vulnerability are not well understood. Using 
several methods, investigations demonstrate 
that despite resistance of the GABAergic 
system to neurodegeneration, particular 
subunits of the GABAA receptor are altered 
with age and AD, which can induce 
compensatory increases in GABAA receptor 
subunits within surrounding cells. Although 
alteration in GABAA may be diffident and 
perhaps low, this may be enough for alteration 
in the pharmacokinetic and physiological 
properties of the receptor. Therefore, it is 
critical to understand the subunit composition 
of individual GABAA receptors in the diseased 
brain when developing therapeutics that act at 
these receptors [80].  
 
GABAA receptors alteration in CNS 
     Genetics variations in gene expression may 
be associated with mental disorders. An 
altered expression of the GABAA receptor has 
neurophysiologic and functional consequences 
that might relate to the behavioral and 
epileptic phenotype associated with fragile X 
syndrome, such as anxiety, depression, 
epilepsy, insomnia, and learning and memory 
[81, 82]. Alteration in GABAergic inhibitory 
action such as alterations in the number of 
GABAA receptors [4], alterations in GABAA 
receptor subunit composition [40, 83, 84], 
increased sensitivity to Zn2+ inhibition of 
GABAA receptors in the dentate granule cells 
[84-86], decreases in GABA transporter 
function [87] disconnection of inhibitory 
interneurons from excitatory inputs [88] and 
use-dependent reduction of excitatory drive to 
inhibitory interneurons [89] is important in the 
generation of epilepsy. Alterations in GABAA 
receptor subunit gene expression also may be 
important in mediating Alzheimer’s disease 
[90, 91], schizophrenia [92-95], and ischemia 
[96, 97]. In severe cases of Alzheimer’s 
disease, levels of 1 subunit protein are 
significantly reduced compared with mild 
cases within the hippocampal subregions CA1, 
CA2, and prosubiculum, but not in the dentate 
gyrus, subiculum, and presubiculum [91]. 
Furthermore, level of 3, but not 2, mRNA is 
reduced in the pathologically severe group in 
all hippocampal subregions except CA4 [90]. 
GABAA receptor subunit mRNA are 
differentially regulated in the prefrontal cortex 
of schizophrenics. While modest reductions in 
, and 2 subunit mRNA 
have been detected by in situ hybridisation 
histochemistry [93], reduced levels of 2S 
transcripts have been observed using 
semiquantative RT-PCR [94]. In human 
temporal lobe epilepsy (TLE), alterations in 
GABA receptor binding have been 
documented [98]. In the CA2 area of TLE 
patients there is a uniform increase in 1, 2, 
2/3, and 2 subunits in the dentate granule 
cell layer, while levels of 2 alone increase. 
Moreover, extensive cell loss in the CA1 and 
CA3 regions is accompanied by a significant 
decrease in the  subunit. Mutations in the 
GABAA receptor 2 subunit [99, 100] and 1 
subunit [101, 102] have been described in 
patients with epilepsy. 
Innate genetic errors caused by dysfunction of 
the GABAergic system have features common 
in many mental disorders. Patients with 1p36 
deletions, missing a series of genes including 
the delta subunit of the GABAA receptor, show 
neurological and neuropsychiatric anomalies 
[103]. The genes encoding the alpha 5, beta 3 
and gamma 3 subunits of the GABAA receptor 
on chromosome 15 are commonly deleted in 
patients with Prader-Willi or Angelman 
syndrome [104] that this altered 
neurobehavioral function of Prader-Willi 
patients could arise directly from an altered 
GABAA receptor composition and expression. 
In addition, beta 3 mutant mice display a 
phenotype similar to some aspects of 
Angelman syndrome, including epilepsy, 
hyperactivity, learning and memory deficits, 
and poor motor skills [105]. It is suggested 
that the associated seizures in some 
experimental mutant mice could be elucidated 
by an imbalanced neurotransmitter 
concentration that led to a pathological 
adjustment of the GABA inhibitory system 
[106, 107]. Significant decrease in mRNA 
expression of GAD67, delta alpha 1, alpha 3 
and alpha 4, beta 1 and beta 2, and gamma 1 
and gamma 2 subunits of the GABAA receptor, 
has been demonstrated in the fragile X mouse 
[82, 108, 109]. 
 
Agents effect on GABAA receptors in 
mental disorder 
    Many drugs that work on the GABAA 
receptor are commercially available. GABAA 
receptors are targets of both various classes of 
clinically relevant drugs, including 
benzodiazepines, barbiturates, and general 
anaesthetics, in addition to endogenous 
components, such as neuroactive steroids, all 
of which allosterically modulate receptor 
function [5, 110].  
Benzodiazepines are widely used as anxiolytic 
agents in many countries even though 
antidepressants are now suggested as the first 
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choice of treatment for anxiety [111], largely 
due to their safety profile. Benzodiazepines are 
very effective in short-term use. A point 
mutation in the GABAA receptor 2 subunit 
in transgenic mouse lines selectively disrupted 
the anxiolytic effects of benzodiazepines, but 
not other pharmacological effects of 
benzodiazepines [112]. This demonstrates a 
key role of the GABAA receptor 2 subunit in 
anxiolytic effects of benzodiazepines.  
     Some neuropsychiatric disorders, such as 
anxiety, epilepsy, sleep disorders and 
convulsive disorders, have been effectively 
treated with therapeutic agents that enhance 
the action of GABA at the GABAA receptor in 
nervous tissue [113]. 
     Expression of specific subtypes of the 
GABAA receptor decrease in fragile X 
syndrome; it is indicate that specific enhancers 
of this receptor might be suitable drugs to treat 
the behavioral aspects of the disorder. These 
compounds with partial agonist properties 
were already reported to have improved 
profiles in whole animal behavioral models 
[114]. 
     The GABA transporter 1 is another novel 
candidate as a promising target for treatment 




     GABA system as a whole and especially 
GABAA receptors have important roles in CNS 
and have also been strongly linked to several 
mental disorders such as epilepsy, anxiety, 
depression and alcoholism with different 
mechanisms. Previous research found 
evidences for association of various GABA 
receptor genes and a range of mental disorder-
related phenotypes. Alteration in GABAergic 
inhibitory action such as alterations in the 
number of GABAA receptors, alterations in 
GABAA receptor subunit composition and 
gene expression of the GABAA receptor has 
neurophysiologic and functional consequences 
that might relate to mental disorders. 
Therefore, the better understanding of 
relationship of GABAA receptors and mental 
disorders potentially could help to find novel 
drugs to overcome aforementioned disorders 
and avoid their side effects. 
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